Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | CFTR | P13569 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19554222 | 0.93 | KDM4E (0.74) | KDM4EPOLBGAACFTRALDH1A1 | |
| SCHEMBL221470 | 0.86 | KDM4E (0.64) | KDM4EPOLBGAACFTRALDH1A1 | |
| SCHEMBL372600 | 0.85 | KDM4E (1.00) | KDM4EPOLBGAACFTRALDH1A1 | |
| SCHEMBL31408659 | 0.85 | KDM4E (1.00) | KDM4EPOLBGAACFTRALDH1A1 | |
| SCHEMBL195591 | 0.85 | KDM4E (0.61) | KDM4EPOLBGAACFTRALDH1A1 | |
| SCHEMBL4165532 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAAALDH1A1MAPK1 | |
| SCHEMBL2310679 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAAALDH1A1HPGD | |
| SCHEMBL7019323 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAAALDH1A1MAPT | |
| SCHEMBL30408027 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAAALDH1A1MAPK1 | |
| SCHEMBL17241781 | 0.84 | KDM4E (0.53) | KDM4EGAAALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250115577-A1 | BCL-2 Inhibitors | Eil Therapeutics, Inc. | 2025-04-10 | — | — | US | disclosed |
| EP-4457223-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118451070-A | BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-111646940-B | Preparation method of bosutinib intermediate | 鲁南制药集团股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023129553-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129553-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-111646940-A | Preparation method of bosutinib intermediate | 鲁南制药集团股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-0635498-B1 | Quinazoline derivatives and their use as anti-cancer agents | SYNGENTA LTD (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-5580870-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0602851-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1996-10-09 | — | — | EP | disclosed |
| US-5475001-A | Quinazoline derivatives | ZENECA LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| WO-1995003283-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | ZENECA LIMITED (GB) | 1995-02-02 | — | — | WO | disclosed |
| EP-0635498-A1 | Quinazoline derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
| EP-0602851-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1994-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | KDM4E 2122/4885POLB 3340/4885GAA 419/4885 |
| US-20250115577-A1 | BCL-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | KDM4E 3326/4885POLB 694/4885GAA 704/4885 |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | ENGASE, UGGT1, MGAT3 | KDM4E 3912/4885POLB 4157/4885GAA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.